Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Changes in Epithelial Ovarian Cancer Treatment and Advent of Maintenance Therapy From Real-World Data

Miyamoto, Emiri ; Mogi, Kazumasa ; Yoshihara, Masato ; Iyoshi, Shohei ; Uno, Kaname LU orcid ; Fujimoto, Hiroki ; Kunishima, Atsushi ; Yoshikawa, Marina ; Kitami, Kazuhisa and Yoshikawa, Nobuhisa , et al. (2026) In Journal of Obstetrics and Gynaecology Research 52(5).
Abstract

Purpose: Ovarian cancer is the most lethal gynecological malignancy, and chemotherapy strategies have evolved substantially over recent decades. This study aimed to evaluate whether survival outcomes of epithelial ovarian cancer (EOC) have improved over time and to explore trends in younger patients of reproductive age. Basic Procedures: We retrospectively analyzed real-world data from the Tokai Ovarian Tumor Study Group. A total of 2824 patients with EOC who were diagnosed between 1986 and 2019 were included. Patients were categorized into three groups according to treatment initiation: Group 1 (1986–1995), Group 2 (1996–2013), and Group 3 (2014 onward). Overall survival (OS) was assessed using the log-rank test, and stratified... (More)

Purpose: Ovarian cancer is the most lethal gynecological malignancy, and chemotherapy strategies have evolved substantially over recent decades. This study aimed to evaluate whether survival outcomes of epithelial ovarian cancer (EOC) have improved over time and to explore trends in younger patients of reproductive age. Basic Procedures: We retrospectively analyzed real-world data from the Tokai Ovarian Tumor Study Group. A total of 2824 patients with EOC who were diagnosed between 1986 and 2019 were included. Patients were categorized into three groups according to treatment initiation: Group 1 (1986–1995), Group 2 (1996–2013), and Group 3 (2014 onward). Overall survival (OS) was assessed using the log-rank test, and stratified analyses were performed by stage and histological subtype. Subgroup analysis was conducted for patients aged ≤ 45 years. Main Findings: Five-year OS differed significantly among the three groups (p < 0.01), demonstrating improved survival over time. Stratified analyses revealed significant benefits in advanced-stage disease and in chemotherapy-sensitive histologies such as serous and endometrioid carcinoma. Clear cell carcinoma showed modest improvement, whereas mucinous carcinoma showed no significant change. Among patients aged ≤ 45 years, five-year OS showed a trend toward improvement but did not reach statistical significance (p = 0.16). Principal Conclusions: Survival outcomes for ovarian cancer have improved in recent decades, particularly in advanced-stage disease and chemotherapy-sensitive subtypes. Advances in systemic therapy, including the introduction of maintenance strategies, likely contributed to this improvement. Continued data accumulation is essential to clarify treatment efficacy in younger patients and to inform fertility-preserving approaches.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
chemotherapy, fertility preservation, ovarian cancer, prognosis, real-world data
in
Journal of Obstetrics and Gynaecology Research
volume
52
issue
5
article number
e70268
publisher
Wiley-Blackwell
external identifiers
  • scopus:105039199183
  • pmid:42134975
ISSN
1341-8076
DOI
10.1111/jog.70268
language
English
LU publication?
yes
id
281ee865-78a9-4f80-a61a-493f7b257f4a
date added to LUP
2026-08-26 09:39:46
date last changed
2026-09-23 11:17:32
@article{281ee865-78a9-4f80-a61a-493f7b257f4a,
  abstract     = {{<p>Purpose: Ovarian cancer is the most lethal gynecological malignancy, and chemotherapy strategies have evolved substantially over recent decades. This study aimed to evaluate whether survival outcomes of epithelial ovarian cancer (EOC) have improved over time and to explore trends in younger patients of reproductive age. Basic Procedures: We retrospectively analyzed real-world data from the Tokai Ovarian Tumor Study Group. A total of 2824 patients with EOC who were diagnosed between 1986 and 2019 were included. Patients were categorized into three groups according to treatment initiation: Group 1 (1986–1995), Group 2 (1996–2013), and Group 3 (2014 onward). Overall survival (OS) was assessed using the log-rank test, and stratified analyses were performed by stage and histological subtype. Subgroup analysis was conducted for patients aged ≤ 45 years. Main Findings: Five-year OS differed significantly among the three groups (p &lt; 0.01), demonstrating improved survival over time. Stratified analyses revealed significant benefits in advanced-stage disease and in chemotherapy-sensitive histologies such as serous and endometrioid carcinoma. Clear cell carcinoma showed modest improvement, whereas mucinous carcinoma showed no significant change. Among patients aged ≤ 45 years, five-year OS showed a trend toward improvement but did not reach statistical significance (p = 0.16). Principal Conclusions: Survival outcomes for ovarian cancer have improved in recent decades, particularly in advanced-stage disease and chemotherapy-sensitive subtypes. Advances in systemic therapy, including the introduction of maintenance strategies, likely contributed to this improvement. Continued data accumulation is essential to clarify treatment efficacy in younger patients and to inform fertility-preserving approaches.</p>}},
  author       = {{Miyamoto, Emiri and Mogi, Kazumasa and Yoshihara, Masato and Iyoshi, Shohei and Uno, Kaname and Fujimoto, Hiroki and Kunishima, Atsushi and Yoshikawa, Marina and Kitami, Kazuhisa and Yoshikawa, Nobuhisa and Kajiyama, Hiroaki}},
  issn         = {{1341-8076}},
  keywords     = {{chemotherapy; fertility preservation; ovarian cancer; prognosis; real-world data}},
  language     = {{eng}},
  number       = {{5}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Journal of Obstetrics and Gynaecology Research}},
  title        = {{Changes in Epithelial Ovarian Cancer Treatment and Advent of Maintenance Therapy From Real-World Data}},
  url          = {{http://dx.doi.org/10.1111/jog.70268}},
  doi          = {{10.1111/jog.70268}},
  volume       = {{52}},
  year         = {{2026}},
}